{"count": 22, "results": [{"_id": "31829964", "pmid": 31829964, "pmcid": "PMC6993269", "title": "Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort", "journal": "Endocr Connect", "authors": ["Jensterle M", "Kravos NA", "Ferjan S", "Goricar K", "Dolzan V", "Janez A"], "date": "2020-01-01T00:00:00Z", "doi": "10.1530/EC-19-0449", "meta_date_publication": "2020 Jan", "meta_volume": "9", "meta_issue": "1", "meta_pages": "44-54", "score": 50266.797, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ therapy", "citations": {"NLM": "Jensterle M, Kravos NA, Ferjan S, Goricar K, Dolzan V, Janez A. Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort Endocr Connect. 2020 Jan;9(1):44-54. PMID: 31829964", "BibTeX": "@article{31829964, title={Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort}, author={Jensterle M and Kravos NA and Ferjan S and Goricar K and Dolzan V and Janez A}, journal={Endocr Connect}, volume={9}, number={1}, pages={44-54}}"}}, {"_id": "38044655", "pmid": 38044655, "title": "Combination of metformin with liraglutide in treating HAIR-AN syndrome in children: A case report and literature review.", "journal": "Zhong Nan Da Xue Xue Bao Yi Xue Ban", "authors": ["Li R", "Li H", "Yang Z", "Zhang X"], "date": "2023-01-01T00:00:00Z", "doi": "10.11817/j.issn.1672-7347.2023.230100", "meta_date_publication": "2023 Sept 28", "meta_volume": "48", "meta_issue": "9", "meta_pages": "1425-1431", "score": 50258.883, "text_hl": "@DISEASE_Obesity @DISEASE_MESH:D009765 @@@Obesity@@@, @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@IR@@@, @DISEASE_Hyperglycemia @DISEASE_MESH:D006943 @@@hyperglycemia@@@, @<m>DISEASE_Dysmenorrhea</m> @DISEASE_MESH:D004412 @@@menstrual disorder@@@, and @DISEASE_Acanthosis_Nigricans @DISEASE_MESH:D000052 @@@AN@@@ were significantly improved after treating with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and liraglutide. ", "citations": {"NLM": "Li R, Li H, Yang Z, Zhang X. Combination of metformin with liraglutide in treating HAIR-AN syndrome in children: A case report and literature review. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Sept 28;48(9):1425-1431. PMID: 38044655", "BibTeX": "@article{38044655, title={Combination of metformin with liraglutide in treating HAIR-AN syndrome in children: A case report and literature review.}, author={Li R and Li H and Yang Z and Zhang X}, journal={Zhong Nan Da Xue Xue Bao Yi Xue Ban}, volume={48}, number={9}, pages={1425-1431}}"}}, {"_id": "35673756", "pmid": 35673756, "title": "[The 495th case: young female-hyperandrogenemia-severe insulin resistance].", "journal": "Zhonghua Nei Ke Za Zhi", "authors": ["Cui YY", "Jiajue JRZ", "Chen MP", "Lu L", "Yu M", "Wang LJ"], "date": "2022-06-01T00:00:00Z", "doi": "10.3760/cma.j.cn112138-20210730-00511", "meta_date_publication": "2022 Jun 1", "meta_volume": "61", "meta_issue": "6", "meta_pages": "703-707", "score": 50245.043, "text_hl": "A 22-year-old female has complained of @DISEASE_Hirsutism @DISEASE_MESH:D006628 @@@hirsutism@@@, @DISEASE_Acanthosis_Nigricans @DISEASE_MESH:D000052 @@@acanthosis nigricans@@@, @DISEASE_Cardiomegaly @DISEASE_MESH:D006332 @@@enlarged clitoris@@@, and @<m>DISEASE_Dysmenorrhea</m> @DISEASE_MESH:D004412 @@@menstrual disorders@@@ since puberty. ", "citations": {"NLM": "Cui YY, Jiajue JRZ, Chen MP, Lu L, Yu M, Wang LJ. [The 495th case: young female-hyperandrogenemia-severe insulin resistance]. Zhonghua Nei Ke Za Zhi. 2022 Jun 1;61(6):703-707. PMID: 35673756", "BibTeX": "@article{35673756, title={[The 495th case: young female-hyperandrogenemia-severe insulin resistance].}, author={Cui YY and Jiajue JRZ and Chen MP and Lu L and Yu M and Wang LJ}, journal={Zhonghua Nei Ke Za Zhi}, volume={61}, number={6}, pages={703-707}}"}}, {"_id": "37364543", "pmid": 37364543, "title": "Curative polyendocrine therapy in a 21 year old patient with endometrial carcinoma. Case report and review of literature.", "journal": "Oncol Res Treat", "authors": ["Schäffler H", "Dimpfl M", "Schochter F", "Janni W", "de Gregorio N"], "date": "2023-06-26T00:00:00Z", "doi": "10.1159/000531661", "meta_date_publication": "2023 Jun 26", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50241.582, "text_hl": "Despite national guidelines recommending a hysterectomy, the nulliparous patient with a desire to have children requested an organ-preserving procedure and underwent polyendocrine therapy with @CHEMICAL_Letrozole @CHEMICAL_MESH:D000077289 @@@Letrozole@@@, @CHEMICAL_Everolimus @CHEMICAL_MESH:D000068338 @@@Everolimus@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and Zoladex. 43 months after diagnosis, the patient gave birth to a healthy child. ", "citations": {"NLM": "Schäffler H, Dimpfl M, Schochter F, Janni W, de Gregorio N. Curative polyendocrine therapy in a 21 year old patient with endometrial carcinoma. Case report and review of literature. Oncol Res Treat. 2023 Jun 26;():. PMID: 37364543", "BibTeX": "@article{37364543, title={Curative polyendocrine therapy in a 21 year old patient with endometrial carcinoma. Case report and review of literature.}, author={Schäffler H and Dimpfl M and Schochter F and Janni W and de Gregorio N}, journal={Oncol Res Treat}}"}}, {"_id": "40580384", "pmid": 40580384, "title": "The Efficacy of Various Weight Loss Strategies in Alleviating Polycystic Ovary Syndrome.", "journal": "Curr Obes Rep", "authors": ["Yang S", "Pan X", "Yang R", "Wang Y", "Zhang Z", "Chen G", "Li Z", "Qiu G", "Li L", "Jing C", "Tian F"], "date": "2025-06-28T00:00:00Z", "doi": "10.1007/s13679-025-00649-5", "meta_date_publication": "2025 Jun 28", "meta_volume": "14", "meta_issue": "1", "meta_pages": "57", "score": 50231.1, "text_hl": "Among pharmacological therapies, glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly when combined with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, have exhibited notable efficacy in managing @DISEASE_Hyperandrogenism @DISEASE_MESH:D017588 @@@hyperandrogenism@@@ and @<m>DISEASE_Dysmenorrhea</m> @DISEASE_MESH:D004412 @@@menstrual disturbances@@@. ", "citations": {"NLM": "Yang S, Pan X, Yang R, Wang Y, Zhang Z, Chen G, Li Z, Qiu G, Li L, Jing C, Tian F. The Efficacy of Various Weight Loss Strategies in Alleviating Polycystic Ovary Syndrome. Curr Obes Rep. 2025 Jun 28;14(1):57. PMID: 40580384", "BibTeX": "@article{40580384, title={The Efficacy of Various Weight Loss Strategies in Alleviating Polycystic Ovary Syndrome.}, author={Yang S and Pan X and Yang R and Wang Y and Zhang Z and Chen G and Li Z and Qiu G and Li L and Jing C and Tian F}, journal={Curr Obes Rep}, volume={14}, number={1}, pages={57}}"}}, {"_id": "34466481", "pmid": 34466481, "pmcid": "PMC8343515", "title": " Effect of Aslagh Capsule, a Traditional Compound Herbal Product on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A Three-Arm, Open-label, Randomized, Controlled Trial ", "journal": "Galen Med J", "authors": ["Bahman M", "Hajimehdipoor H", "Bioos S", "Hashem-Dabaghian F", "Afrakhteh M", "Tansaz M"], "date": "2019-06-02T00:00:00Z", "doi": "10.31661/gmj.v8i0.1261", "meta_date_publication": "2019", "meta_volume": "8", "meta_issue": "", "meta_pages": "e1261", "score": 50060.504, "text_hl": "This rate was 32 (86.5%) in the Aslagh group, 35 (89.7%) in the @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ group, and 35 (85.4%) in the Aslagh + @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ group. ", "citations": {"NLM": "Bahman M, Hajimehdipoor H, Bioos S, Hashem-Dabaghian F, Afrakhteh M, Tansaz M.  Effect of Aslagh Capsule, a Traditional Compound Herbal Product on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A Three-Arm, Open-label, Randomized, Controlled Trial  Galen Med J. 2019;8():e1261. PMID: 34466481", "BibTeX": "@article{34466481, title={ Effect of Aslagh Capsule, a Traditional Compound Herbal Product on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A Three-Arm, Open-label, Randomized, Controlled Trial }, author={Bahman M and Hajimehdipoor H and Bioos S and Hashem-Dabaghian F and Afrakhteh M and Tansaz M}, journal={Galen Med J}, volume={8}, pages={e1261}}"}}, {"_id": "26822064", "pmid": 26822064, "title": "Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review.", "journal": "Psychiatry Res", "authors": ["Bo QJ", "Wang ZM", "Li XB", "Ma X", "Wang CY", "de Leon J"], "date": "2016-03-30T00:00:00Z", "doi": "10.1016/j.psychres.2016.01.031", "meta_date_publication": "2016 Mar 30", "meta_volume": "237", "meta_issue": "", "meta_pages": "257-63", "score": 50055.277, "text_hl": "Adjunctive @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for antipsychotic-induced @DISEASE_Hyperprolactinemia @DISEASE_MESH:D006966 @@@hyperprolactinemia@@@: A systematic review.", "citations": {"NLM": "Bo QJ, Wang ZM, Li XB, Ma X, Wang CY, de Leon J. Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review. Psychiatry Res. 2016 Mar 30;237():257-63. PMID: 26822064", "BibTeX": "@article{26822064, title={Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review.}, author={Bo QJ and Wang ZM and Li XB and Ma X and Wang CY and de Leon J}, journal={Psychiatry Res}, volume={237}, pages={257-63}}"}}, {"_id": "19056992", "pmid": 19056992, "title": "Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.", "journal": "Endocr Rev", "authors": ["Palomba S", "Falbo A", "Zullo F", "Orio F Jr"], "date": "2009-02-01T00:00:00Z", "doi": "10.1210/er.2008-0030", "meta_date_publication": "2009 Feb", "meta_volume": "30", "meta_issue": "1", "meta_pages": "1-50", "score": 50055.086, "text_hl": "In particular, we will analyze the uses of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ not only for the treatment of all @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@-related disturbances such as @<m>DISEASE_Dysmenorrhea</m> @DISEASE_MESH:D004412 @@@menstrual disorders@@@, @DISEASE_Infertility @DISEASE_MESH:D007246 @@@anovulatory infertility@@@, increased @DISEASE_Abortion_Habitual @DISEASE_MESH:D000026 @@@abortion@@@, or complicated pregnancy risk, @DISEASE_Hyperandrogenism @DISEASE_MESH:D017588 @@@hyperandrogenism@@@, endometrial, @DISEASE_Cardiovascular_Abnormalities @DISEASE_MESH:D018376 @@@metabolic and cardiovascular abnormalities@@@, but also for the prevention of the syndrome.", "citations": {"NLM": "Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009 Feb;30(1):1-50. PMID: 19056992", "BibTeX": "@article{19056992, title={Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.}, author={Palomba S and Falbo A and Zullo F and Orio F Jr}, journal={Endocr Rev}, volume={30}, number={1}, pages={1-50}}"}}, {"_id": "9548159", "pmid": 9548159, "title": "Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.", "journal": "Fertil Steril", "authors": ["Morin-Papunen LC", "Koivunen RM", "Ruokonen A", "Martikainen HK"], "date": "1998-04-01T00:00:00Z", "doi": "10.1016/s0015-0282(98)00011-9", "meta_date_publication": "1998 Apr", "meta_volume": "69", "meta_issue": "4", "meta_pages": "691-6", "score": 50054.258, "text_hl": "There was no significant change in the levels of other sex steroids or @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipids@@@ measured at 4-6 months of treatment. CONCLUSION(S): @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ therapy is well tolerated by the majority of @SPECIES_9606 @@@patients@@@ and may be clinically useful, especially in @DISEASE_Obesity @DISEASE_MESH:D009765 @@@obese@@@ @SPECIES_9606 @@@patients@@@ with @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@ and @<m>DISEASE_Dysmenorrhea</m> @DISEASE_MESH:D004412 @@@menstrual disturbances@@@.", "citations": {"NLM": "Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998 Apr;69(4):691-6. PMID: 9548159", "BibTeX": "@article{9548159, title={Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.}, author={Morin-Papunen LC and Koivunen RM and Ruokonen A and Martikainen HK}, journal={Fertil Steril}, volume={69}, number={4}, pages={691-6}}"}}, {"_id": "10634377", "pmid": 10634377, "title": "Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.", "journal": "J Clin Endocrinol Metab", "authors": ["Moghetti P", "Castello R", "Negri C", "Tosi F", "Perrone F", "Caputo M", "Zanolin E", "Muggeo M"], "date": "2000-01-01T00:00:00Z", "doi": "10.1210/jcem.85.1.6293", "meta_date_publication": "2000 Jan", "meta_volume": "85", "meta_issue": "1", "meta_pages": "139-46", "score": 50053.438, "text_hl": "After @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment, mean frequency of menstruation improved (P = 0.002), due to striking amelioration of @<m>DISEASE_Dysmenorrhea</m> @DISEASE_MESH:D004412 @@@menstrual abnormalities@@@ in about 50% of subjects. ", "citations": {"NLM": "Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000 Jan;85(1):139-46. PMID: 10634377", "BibTeX": "@article{10634377, title={Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.}, author={Moghetti P and Castello R and Negri C and Tosi F and Perrone F and Caputo M and Zanolin E and Muggeo M}, journal={J Clin Endocrinol Metab}, volume={85}, number={1}, pages={139-46}}"}}]}